



Date: 04/02/2021

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 Oct 2020 to 31 Dec 2020** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
JAYMIN SHAH & ASSOCIATES



Date: 04/02/2021

Place: Ahmedabad

UDIN: 21170863AAAABS1390

Corp. Office : 410 411, Lilamani Corporate Heights, Opp. Ramapir Brts Bus Stand, Nr. Ozone Aangan, New Wadaj, Ahmedabad - 380013, Gujarat
Branch Office : 504, Palladium Business Hub, Above Pantaloons, Opp. 4D Mall - PVR Cinema, Visat-Gandhinagar Highway, Ahmedabad 382424

- CA Mayank Sancheti +91 8000331632 / 7048685472
- Deepak Surana +91 9429913706
- GSTIN : 24AAOFJ1119R1ZY

✉ camayanksancheti@gmail.com
dpaksurana4u@gmail.com



Unaudited Financial Results for the Quarter Ended December 31, 2020

Particulars	Amount in Lacs except Per Share data											
	Quarter Ended			Period Ended			Year Ended					
	3 Months Ended Un-audited 31-Dec-20	3 Months Ended Un-audited 30-Sep-20	3 Months Ended Un-audited 31-Dec-19	9 Months Ended Un-audited 31-Dec-20	9 Months Ended Un-audited 31-Dec-19	12 Months Ended Audited 31-Mar-20						
1 INCOME												
Revenue from Operations	382,979	379,629	398,481	993,009	1,145,307	1,481,812						
Other Income	1,027	3,683	6,933	5,090	12,252	17,646						
Total Income	384,006	383,312	405,414	998,099	1,157,559	1,499,458						
2 EXPENSES												
(a) Cost of Material Consumed	272,523	303,691	340,665	730,130	916,356	1,135,527						
(b) Purchase of Stock-In-Trade	12,664	0.000	0.000	14,133	2,903	9,253						
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	14,048	-9,285	-15,963	2,166	-8,005	-0,265						
(d) Employee Benefit Expense	28,090	25,902	27,167	79,603	80,435	109,795						
(e) Finance Cost	0.513	0.618	0.939	1,698	2,913	3,470						
(f) Depreciation, Depletion and Amortisation Expense	4,437	4,436	3,893	13,310	11,693	17,747						
(g) Other Expense	32,514	38,814	31,461	106,644	101,624	152,587						
Total Other Expenses	32,514	38,814	31,461	106,644	101,624	152,587						
Total Expenses	364,789	364,176	388,162	947,684	1,107,919	1,428,114						
Total Profit before Exceptional Items and Tax	19,217	19,137	17,252	50,415	49,640	71,344						
Exceptional Items	0.000	0.000	0.000	0.000	0.000	0.000						
Total Profit before Tax	19,217	19,137	17,252	50,415	49,640	71,344						
Tax Expense												
Current Tax	5,500	4,000	4,886	12,500	12,400	17,500						
Deferred Tax	0.000	0.000	0.000	0.000	0.000	-0,870						
Total Tax Expenses	5,500	4,000	4,886	12,500	12,400	16,630						
Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.000	0.000	0.000	0.000	0.000	0.000						
Net Profit Loss for the period from continuing operations	13,717	15,137	12,366	37,915	37,240	54,714						
Profit / (Loss) from discontinued operations before tax	0.000	0.000	0.000	0.000	0.000	0.000						
Tax Expenses of discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000						
Net Profit / (Loss) from discontinued operations after tax	0.000	0.000	0.000	0.000	0.000	0.000						
Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.000	0.000	0.000	0.000	0.000	0.000						
Total Profit / (Loss) for the period	13,717	15,137	12,366	37,915	37,240	54,714						
Other Comprehensive Income net of Taxes	0.000	0.000	0.000	0.000	0.000	0.000						
Total Comprehensive Income for the Period	13,717	15,137	12,366	37,915	37,240	54,714						
Total profit or loss attributable to												
Profit or loss, attributable to owners of parents	0.000	0.000	0.000	0.000	0.000	0.000						
Total Profit or loss, attributable to non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000						
Total comprehensive income for the period attributable to												

Jyoti Arora

	Comprehensive income for the period attributable to the owners of parents	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
21	Details of Equity Share Capital								
	Paid-Up Equity Share Capital	299.030	299.030	299.030	299.030	299.030	299.030	299.030	299.030
	Face Value of Equity Share Capital	10.000	10.000	10.000	10.000	10.000	10.000	10.000	10.000
22	Details of Debt Securities								
	Paid-Up Debt Capital	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
	Face Value of Debt Securities	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
23	Reserves Excluding Revaluation Reserves	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
24	Debt Redemption Reserve	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
25	Earnings Per Share								
(i)	Earnings Per Share for continuing operations								
	Basic Earnings / (Loss) per share from continuing operations	0.459	0.506	0.414	1.268	1.245	1.245	1.830	1.830
	Diluted Earnings / (Loss) per share from continuing operations	0.459	0.506	0.414	1.268	1.245	1.245	1.830	1.830
(ii)	Earnings Per Share for discontinued operations								
	Basic Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
	Diluted Earnings / (Loss) per share from discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
(iii)	Earnings per Equity Share								
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.459	0.506	0.414	1.268	1.245	1.245	1.830	1.830
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.459	0.506	0.414	1.268	1.245	1.245	1.830	1.830
26	Debt Equity Ratio*	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
27	Debt Service Coverage Ratio*	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
28	Interest Service Coverage Ratio*	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
	* The Company has no long term debt as on date								

NOTES

- The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 04, 2021.
- The Limited Review of the results has been completed by the Statutory Auditors of the Company.
- As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
- Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
- Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jyotirm Agrawal

Place Ahmedabad
Date 4-Feb-2021

JAGDISH AGRAWAL
MANAGING DIRECTOR
DIN: 01031687